• OFID 2017:4 (Suppl 1) • Poster Abstracts length of stay (LOS), ICU LOS, 90-day incidence of extended spectrum β-lactamases (ESBLs), and 30-day readmission rates and incidence of Clostridium difficile. Adverse events including acute kidney injury and QTc prolongation were also evaluated preand post-implementation of the guideline.
Background. For patients at risk for multidrug resistant organisms, IDSA/ATS guidelines recommend empiric therapy with 1 agent against methicillin-resistant Staphylococcus aureus (MRSA) and another against Pseudomonas. Following negative cultures, guidelines are unclear regarding antibiotic de-escalation. We assessed de-escalation and associated outcomes in a cohort of pneumonia patients with negative cultures.
Methods. We included adults admitted with pneumonia from 2010-2015 to 168 US hospitals if they had blood/respiratory cultures and received vancomycin together with an antipseudomonal drug other than a quinolone by hospital day 1. We excluded patients with positive cultures, death or discharge by day 4. De-escalation was defined as stopping both drugs by day 4, but continuing another antibiotic. Patients were matched on propensity for de-escalation and compared on late deterioration, inpatient mortality, length of stay (LOS), cost and 30-day readmission. The propensity model included demographics, co-morbidities and treatments on day 4, which served as proxies for clinical severity. We also compared adjusted outcomes across hospital quartile of de-escalation.
Results. Of 22,400 patients included, 4121 (18.4 %) had both drugs stopped within 4 days. Median age was 72 years, 56% were female, and 39% were admitted to the intensive care unit (ICU). Compared with patients without de-escalation, those de-escalated had similar demographics, but fewer co-morbidities and less severe disease at days 1 and 4. After propensity-matching, there were no significant differences in 83 variables. In the matched sample, de-escalated patients had lower odds of inpatient mortality (OR 0.71, 95% CI 0.60 -0.83), subsequent transfer to ICU (OR 0.31; 95% CI 0.19 -0.52), LOS (OR 0.79, 95% CI 0.77 -0.80) and lower costs (OR 0.79, 95% CI 0.77 -0.80). Hospital rates of de-escalation ranged from 0-67%. Hospital de-escalation quartile was not significantly associated with any outcome.
Conclusion. In a sample of US hospitals, <20% of pneumonia patients had antibiotic coverage de-escalated following negative cultures, but it varied widely by hospital. Hospitals with high rates of de-escalation did not have worse outcomes. Following negative cultures, de-escalation appears safe in selected patients. Background. With the release of the 2005 IDSA/ATS pneumonia guidelines healthcare providers were advised to consider numerous patient risk factors for multidrug resistant organisms. Furthermore, these guidelines encouraged empiric treatment with two agents active against pseudomonas, based on the assumption that combination therapy increases treatment success. An evaluation of our institution's respiratory cultures revealed that levofloxacin covers only 2% of pseudomonas isolates resistant to piperacillin-tazobactam, and no isolates resistant to cefepime or meropenem.
Evaluation of the Empiric use of Levofloxacin in Combination with
Our primary objective was to correlate this evaluation's findings with patient outcomes by comparing mortality rates experienced by patients receiving levofloxacin plus an antipseudomonal β-lactam vs. those receiving β-lactam alone for the empiric treatment of pneumonia. Secondary objectives were to identify between group differences in length of stay, 30-day readmission, duration of mechanical ventilation, and occurrence of Clostridium difficile infection.
Methods. This single-center, retrospective chart review was conducted by evaluating records of patients with a discharge diagnosis of pneumonia from January 1, 2014 to September 1, 2016. Patients were included if they received at least 48 hours of empiric pneumonia treatment with an IV anti-MRSA agent plus an antipseudomonal β-lactam. Patient enrollment is displayed in Figure 1 .
Results. Of 1897 patient screened, 228 patients were included. There were 146 patients who received monotherapy with an antipseudomonal β-lactam and 82 patients who additionally received levofloxacin. Baseline characteristics were comparable between groups. The mean age was 68.8 years, 51% were male, 45.6% had a diagnosis of COPD at baseline, and the average qSOFA score upon admission was 0.66. There was no significant difference in mortality (P = 0.438), nor any secondary objective. No significant difference in the duration of therapies prior to de-escalation was observed (P = 0.395).
Conclusion. Addition of levofloxacin to β-lactam therapy did not impact clinical outcomes in this population. Further analysis of site-specific data is warranted, as the results of this study may not be generalizable.
